SCHEMBL30950243

SCHEMBL30950243

CC(C)(C)OC(=O)N1CCN(c2c(C#N)c(Cl)nc3c(Oc4c(Cl)c(Cl)cc5[nH]ncc45)cccc23)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KRAS P01116 2/20 0.38
▸ NR1H2 P55055 1/20 0.37
▸ NR1H3 Q13133 1/20 0.37
▸ KCNH2 Q12809 1/20 0.36
▸ PARP1 P09874 1/20 0.34
▸ IDO1 P14902 1/20 0.34
▸ TDO2 P48775 1/20 0.34
▸ TRPV1 Q8NER1 4/20 0.34
▸ ALK Q9UM73 2/20 0.34
▸ SUV39H2 Q9H5I1 2/20 0.34
▸ GPR119 Q8TDV5 1/20 0.34
▸ MAPK8 P45983 1/20 0.33
▸ TNF P01375 1/20 0.33
▸ LITAF Q99732 1/20 0.33
▸ CCNK O75909 1/20 0.33
▸ CCNA2 P20248 1/20 0.33
▸ CDK2 P24941 1/20 0.33
▸ CCND3 P30281 1/20 0.33
▸ CDK9 P50750 1/20 0.33
▸ CDK6 Q00534 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28673619 1.00 KRAS (0.38) KRASNR1H2NR1H3KCNH2PARP1
SCHEMBL28929882 0.94 KCNH2 (0.36) KRASNR1H2NR1H3KCNH2PARP1
SCHEMBL30950272 0.94 KCNH2 (0.36) KRASNR1H2NR1H3KCNH2PARP1
SCHEMBL28654715 0.94 KCNH2 (0.35) KRASNR1H2NR1H3KCNH2PARP1
SCHEMBL30950231 0.94 KCNH2 (0.35) KRASNR1H2NR1H3KCNH2PARP1
SCHEMBL28669680 0.93 KRAS (0.42) KRASNR1H2NR1H3KCNH2PARP1
SCHEMBL30950264 0.93 KRAS (0.42) KRASNR1H2NR1H3KCNH2PARP1
SCHEMBL30950217 0.89 KCNH2 (0.35) NR1H2NR1H3KCNH2PARP1TRPV1
SCHEMBL28655570 0.89 KCNH2 (0.35) NR1H2NR1H3KCNH2PARP1TRPV1
SCHEMBL28655528 0.83 KRAS (0.43) KRASPARP1TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113637005-B KRAS inhibitors for cancer treatment 泰励生物科技(上海)有限公司 2024-05-24 — — CN disclosed
Send feedback